DK0826695T3 - Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer - Google Patents

Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer

Info

Publication number
DK0826695T3
DK0826695T3 DK97115188T DK97115188T DK0826695T3 DK 0826695 T3 DK0826695 T3 DK 0826695T3 DK 97115188 T DK97115188 T DK 97115188T DK 97115188 T DK97115188 T DK 97115188T DK 0826695 T3 DK0826695 T3 DK 0826695T3
Authority
DK
Denmark
Prior art keywords
stem cell
destruction
tumor cells
bispecific antibodies
cell grafts
Prior art date
Application number
DK97115188T
Other languages
English (en)
Inventor
Horst Dr Lindhofer
Helge Dr Menzel
Hans-Jochem Prof Dr Kolb
Stefan Prof Dr Thierfelder
Original Assignee
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19649223A external-priority patent/DE19649223C2/de
Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt
Application granted granted Critical
Publication of DK0826695T3 publication Critical patent/DK0826695T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97115188T 1996-09-03 1997-09-02 Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer DK0826695T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19635743 1996-09-03
DE19649223A DE19649223C2 (de) 1996-09-03 1996-11-27 Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern

Publications (1)

Publication Number Publication Date
DK0826695T3 true DK0826695T3 (da) 2002-04-15

Family

ID=26028996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97115188T DK0826695T3 (da) 1996-09-03 1997-09-02 Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer

Country Status (6)

Country Link
US (2) US5985276A (da)
EP (1) EP0826695B1 (da)
JP (1) JP3257970B2 (da)
AT (1) ATE210682T1 (da)
DK (1) DK0826695T3 (da)
ES (1) ES2169299T3 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0826695T3 (da) * 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO2000018435A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US7208152B2 (en) * 1999-11-24 2007-04-24 Millennium Pharmaceuticals, Inc. Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
US6319675B1 (en) 1999-11-24 2001-11-20 Millennium Pharmaceuticals, Inc. Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
CA2409991A1 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
JP4214249B2 (ja) * 2001-07-30 2009-01-28 学校法人慶應義塾 Ｆｃ受容体γ鎖活性化物質を含有する医薬組成物
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2005077065A2 (en) * 2004-02-09 2005-08-25 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
US8066989B2 (en) * 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
EP1962961B1 (en) * 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
WO2007134274A2 (en) * 2006-05-12 2007-11-22 Attenuon, Llc Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
WO2008140493A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
CN102083850B (zh) 2008-04-21 2015-08-12 加利福尼亚大学董事会 选择性高亲和力多齿配体及其制备方法
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
HUE036157T2 (hu) 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
EP3323830B1 (en) 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
PT3434767T (pt) * 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
US11208474B2 (en) 2016-11-16 2021-12-28 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL23 specific antibody
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018140121A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
JP2021502349A (ja) 2017-11-06 2021-01-28 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
BR112020025987A2 (pt) 2018-06-21 2021-03-23 Yumanity Therapeutics, Inc. composições e métodos para tratamento e prevenção de distúrbios neurológicos
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
MA56124A (fr) 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20210347880A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2022013745A1 (en) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
IL305802A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
EP4423126B1 (en) 2021-10-29 2026-05-06 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP4433501A1 (en) 2021-11-15 2024-09-25 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4526342A1 (en) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
AU2023383916A1 (en) 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US5320942A (en) * 1987-02-19 1994-06-14 Vito Quaranta Method of diagnosing the presence of abnormal epithelial tissue using monoclonal antibodies to the A6 B4 cell surface protein
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
DK0826695T3 (da) * 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer

Also Published As

Publication number Publication date
US5985276A (en) 1999-11-16
JP3257970B2 (ja) 2002-02-18
EP0826695A1 (de) 1998-03-04
EP0826695B1 (de) 2001-12-12
ATE210682T1 (de) 2001-12-15
JPH10179151A (ja) 1998-07-07
US6210668B1 (en) 2001-04-03
ES2169299T3 (es) 2002-07-01

Similar Documents

Publication Publication Date Title
DK0826695T3 (da) Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
ATE196607T1 (de) Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
AU664801B2 (en) Humanised antibodies
ATE248192T1 (de) HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
DK0826696T3 (da) Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
EP1016867A4 (en) IMMUNOASSAY FOR DETERMINING BNP
DE69638355D1 (de) Anti-CD3-Antikörper zur Verwendung zur Induzierung von Immunsuppression
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
NO955314L (no) Immunoanalyser for opplöselige fibrinpolymerer
AU6054398A (en) Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
ATE125362T1 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
DK0752869T3 (da) Celler med talrige ændrede epitoper på et overfladeantigen til anvendelse ved transplantationen
ES2150573T3 (es) Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
CA2198958A1 (en) Method for amplification of the response signal in a sandwich immunoassay
GB2128630A (en) Method of affinity purification employing monoclonal antibodies
EP0307754A3 (en) Method for obtaining a papain-free antibody fragment preparation
ES2157979T3 (es) Titulacion inmunologica competitiva por medio de una proteina de union utilizada en una estructura de anticuerpos multiclonal.
GR3031607T3 (en) Selective system scan for multizone radiotelephone subscriber units.
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
ES2056919T3 (es) Anticuerpo monoclonal especifico para la fosfolipasa a2 pancreatica humana.
ATE80467T1 (de) Immuntestverfahren.
EP0323802A3 (en) Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
DE59710330D1 (de) Hybridzelle und deren Verwendung zur Herstellung eines Arzneimittels zur Induktion einer Tumorimmunität